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Edited by Ivan SadowskiAbstract An osteoclastic protein-tyrosine phosphatase, PTP-
oc, shares the same gene with a renal PTP, Glepp1. This study
demonstrated that targeted deletion of PTP-oc promoter by
homologous recombination in RAW264.7 cells completely abol-
ished PTP-oc expression without aﬀecting Glepp1 expression.
This strategy to inhibit PTP-oc function has three advantages
over commonly used gene knock down strategies (e.g., small
interference RNA). This strategy: (1) yielded cells completely de-
void of PTP-oc, (2) had no oﬀ-target gene silencing eﬀects, and
(3) did not aﬀect Glepp1 expression. The inability of PTP-oc-
deﬁcient RAW264.7 cells to undergo RANKL-mediated osteo-
clastic diﬀerentiation conﬁrmed a regulatory role for PTP-oc
in RANKL-mediated osteoclast diﬀerentiation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Our laboratory has previously identiﬁed a structurally un-
ique, osteoclastic transmembrane protein-tyrosine phospha-
tase, termed PTP-oc, which has a very short extracellular
domain, lacks a signal peptide, and contains only a single
PTP catalytic domain [1]. Our in vitro studies suggested that
PTP-oc may function as a positive regulator of osteoclast
activity in part through dephosphorylation and subsequent
activation of the c-Src protein-tyrosine kinase [2–5]. There is
also in vitro evidence that PTP-oc may also be involved inAbbreviations: PTP, protein-tyrosine phosphatase; TRACP, tartrate-
resistant acid phosphatase; PD-, phosphatase-deﬁcient-; siRNA, small
interference RNA; DMEM, Dulbecco’s modiﬁed Eagle’s medium;
RANK, receptor activator of NFjB; RANKL, RANK ligand; FBS,
fetal bovine serum; pPTP-oc, PTP-oc promoter; RT-PCR, reverse
transcriptase-polymerase chain reaction; KO, knockout; Mitf,
microphthalmia-associated transcription factor; BAC, bacterial artiﬁ-
cial chromosome; HSV-TK, herpes simplex virus thymidine kinase;
GAPDH, glyceraldehyde phosphate dehyrogenase
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doi:10.1016/j.febslet.2007.04.063osteoclast diﬀerentiation, since overexpression of PTP-oc in
pre-osteoclastic U937 cells [3] or RAW264.7 cells [5] increased
the number of tartrate-resistant acid phosphatase (TRACP)
positive, multinucleated osteoclast-like cells, and since expres-
sion of a phosphatase-deﬁcient (PD) PTP-oc mutant [3,5] or
suppression of PTP-oc expression with small interference
RNA (siRNA) [5] reduced the receptor activator of NFjB li-
gand (RANKL)-mediated formation of osteoclast-like cells.
However, the eﬀects of PTP-oc on osteoclast diﬀerentiation
are probably not mediated through c-Src-dependent pathways,
since there is compelling evidence arguing against a role for
c-Src in osteoclast diﬀerentiation [6].
One of the most direct approaches to conﬁrm the physiolog-
ical function of PTP-oc is to evaluate the eﬀects of knocking
out PTP-oc gene expression on osteoclast formation and/or
activity in vivo. However, PTP-oc shares the same exons with
the transmembrane and intracellular domains of a renal recep-
tor PTP, Glepp1 (also known as PTP-U2, PTPRO, PTP-/,
CRYP2, or PTP-BK [7]), on human chromosome 12p12-p13
[8] or mouse chromosome 6 [9]. Thus, the commonly used
strategies for producing knockout mice (i.e., exon interruption
or deletion) would abolish both PTP-oc and Glepp1 gene
expression. Because Glepp1 (expressed in kidney, brain,
spleen, and hematopoietic cells [1]) plays an important role
in the kidney function [10], and the kidney is one of the key or-
gans that regulate bone mineral metabolism, simultaneous
knocking out both Glepp1 and PTP-oc in vivo could confound
the interpretation of the results concerning the physiological
role of PTP-oc in the bone.
Although PTP-oc had been assumed to be a splicing variant
of Glepp1 [11], we [12] and others [13] have provided strong
evidence for the existence of a promoter within intron 12 of
the human Glepp1 gene that drives the cell-type-speciﬁc
expression of PTP-oc in cells of osteoclastic and hematopoietic
lineage. We postulate that it is possible to create PTP-oc
knockout mice with normal levels of Glepp1 expression by tar-
geted inactivation or deletion of the PTP-oc intronic promoter
through a homologous recombination approach. However, the
feasibility of the novel approach to knockout expression of a
speciﬁc gene through promoter deletion has never been dem-
onstrated previously. Therefore, the primary objective of this
study was to demonstrate the feasibility of this approach in a
murine pre-osteoclastic cell line, RAW264.7 cells. This work
became feasible, since we have very recently identiﬁed and
characterized the murine PTP-oc basal promoter [14]. Theblished by Elsevier B.V. All rights reserved.
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abolish the RANKL-mediated formation of osteoclast-like
cells in vitro.2. Materials and methods
2.1. Cell cultures
A subclonal line of murine monocytic pre-osteoclastic RAW264.7
cells [15], a generous gift of Dr. Ian Cassady of the University of
Queensland (Brisbane, Australia), were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Mediatech Inc., Herndon, VA)
supplemented with 10% fetal bovine serum (FBS, Life Technologies,
Grand Island, NY). Cell medium was changed every 2–3 days.
2.2. Replacement targeting (pNTK-pPTP-oc) plasmid
To construct a replacement targeting plasmid intended to delete a
819-bp DNA sequence (567/+252) containing the basal PTP-oc pro-
moter (pPTP-oc) along with a part the 5 0-UTR of PTP-oc, a 2.2 kb
DNA fragment homologous to the DNA sequence upstream to the de-
leted (pPTP-oc) sequence and a 2.5 kb DNA fragment homologous to
the DNA sequence immediately downstream to the deleted region were
generated by long PCR using the genomic DNA of the bacterial artiﬁ-
cial chromosome (BAC) clone RPCI23-125A24 as the template. [This
188-kb murine genomic BAC clone RPCI23-125A24, purchased from
the BACPAC Resource Center (Oakland, CA), contained the entire
murine PTP-oc gene and the intronic promoter sequence.] The PCR
ampliﬁcation was performed with the high ﬁdelity Pfu native DNA
polymerase (Strategene, La Jolla, CA), after a 5 min hot start at
94 C, for 35 cycles of 1 min denaturation at 94 C, 1 min annealing
at 57 C, 7 min extension at 72 C, and concluded with the ﬁnal
10 min incubation at 72 C. Each PCR product was isolated, expanded,
puriﬁed, and conﬁrmed by DNA sequencing. The 2.2-kb homologous
to the 5 0-end DNA sequence was cloned into the BamHI site of the
7-kb pNTK vector (a gift from Dr. Richard Mortensen of the Univer-
sity of Michigan) and the 2.5-kb homologous to the 3 0-end sequenceFig. 1. The schematic description of the experimental strategy for
targeted deletion of murine PTP-oc promoter through the homologous
recombination approach in murine RAW264.7 cells.cloned into the ClaI/XhoI sites, ﬂanking the phosphoglycerate kinase
(PGK) promoter-driven neo gene (Fig. 1). The 11.7-kb pNTK-pPTP-
oc replacement targeting construct was conﬁrmed with DNA sequenc-
ing and restriction mapping.
2.3. Homologous recombination
The pNTK-pPTP-oc plasmid was linearized with NotI. The transfec-
tion of RAW264.7 cells with the replacement plasmid was accom-
plished by electroporation using a GenePulser Xcell system (BioRad
Labs., Hercules, CA). Brieﬂy, the linearized replacement targeting
plasmid (1 lg) in 5 ll of the nucleofection reagent (Amaxa, Gaithers-
burg, MD) was electroporated into RAW264.7 cells (50,000 cells/ml)
at room temperature with 10 bursts of 10 pulses per burst at 450 V.
The transfected cells were plated in DMEM supplemented with 10%
FBS and 0.4 mg/ml of G418 and 2 lM GANC (acyclovir). The pNTK
vector used the neo gene as the positive selection marker gene, as the
recombinant cells containing the neo gene were resistant to G418.
The herpes simplex virus thymidine kinase (HSV-TK) was used as a
negative selection marker gene. Non-homologous recombinant cells,
which had the HSV-TK gene, were killed oﬀ by GANC. The homolo-
gous pPTP-oc KO recombinant cells were selected and expanded in the
presence of G418 and GANC for three weeks (Fig. 1) and were used
for characterization within a month.
2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Brieﬂy, total RNA was isolated from parental or PTP-oc KO
RAW264.7 cells with the RNeasy Mini Kit (Qiagen Inc., Valencia,
CA). The integrity of RNA was determined by the bioanalyzer 2100
(Agilent Technologies, Palo Alto, CA). The RT reaction was carried
out using the Superscript II reverse transcriptase (Invitrogen, Carls-
bad, CA), and the PCR ampliﬁcation was performed with the platinum
Taq DNA polymerase (Invitrogen) for 35 cycles of 94 C for 45 s,
52 C for 45 s, and 72 C for 45 s with a 2-min hot start at 94 C. A
housekeeping gene, b-actin or glyceraldehyde phosphate dehyrogenase
(GAPDH) was included in each experiment for comparison. The PCR
products were analyzed on 1% agarose gels. Oligonucleotide primer
sets for each test gene, synthesized by IDT (Coralville, IA), were de-
signed with the software program at the www.idtdna.com/SciTools/
SciTools.aspx and are shown in Table 1.
2.5. Real-time RT-PCR
Real-time RT-PCR was performed using gene-speciﬁc primers
(Table 1) and the Quantitect SYBR Green detection system (Qiagen)
on a DNA Engine Opticon 2 thermal cycler (BioRad Labs.). The
PCR was performed at a 30 s per step for 30 cycles of denaturation
at 95 C, annealing at 53 C, and extension at 72 C after an initial
hot start at 95 C for 10 min. The relative level of each respective
mRNA was determined by the DCT method (CT for the gene-of-inter-
est – CT of b-actin).
2.6. PTP-oc Western immunoblot assay
Western immunoblots for PTP-oc protein were performed as previ-
ously described [2,4,5] using a polyclonal antibody against the unique
region of the N-terminus of rabbit PTP-oc.
2.7. Diﬀerentiation of RAW264.7 cells into osteoclast-like cells
Formation of osteoclast-like cells were performed as described pre-
viously [5].
2.8. Statistical analysis
Statistical signiﬁcance was determined with two-tailed Student’s
t-test. The diﬀerence was considered signiﬁcant, when P < 0.05.3. Results and discussion
Murine pre-osteoclastic RAW264.7 cells express both PTP-
oc and Glepp1 and, thus, are an appropriate cell model for
the in vitro testing of the feasibility of the approach to knock
out PTP-oc expression, but maintaining the expression of
Glepp1, through deletion of the PTP-oc promoter. For this
work, we constructed the pNTK-pPTP-oc replacement target-
Table 1
Gene-speciﬁc primer sets used for RT-PCR and real-time RT-PCR measurements of mouse gene expression
Gene Primer sequence PCR product size (bps)
PTP-oc Forward CTGCCGTTGGATGTAGG 330
Reverse AGAGCCGAGCTGCTGACAGA
Glepp1 Forward TAAATCGAGTCCCTGCTGTGCAGT 489
Reverse AGGAGCACACTCGCTCAGTTTCTT
c-Fos Forward TCCGTCTCTAGTGCCAACTT 341
Reverse CGCTTGGAGTGTATCTGTCA
Mitf Forward GACATCATCAGCCTGGAATC 388
Reverse ACAGAGGCCTTGAGAATGGT
PU.1 Forward CGCAGCTACAGCAGCTCTAT 292
Reverse GAACTGGTACAGGCGAATCT
RANK Forward CACTCCTACCTCCGACAGTG 275
Reverse GTGCACACCGTATCCTTGTT
GAPDH Forward ATGGTGAAGGTCGGTGTGAA 998
Reverse TTACTCCTTGGAGGCCATGT
b-Actin Forward CAGGCATTGCTGACAGGATG 272
Reverse TGCTGATCCACATCTGCTGG
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(567/+252) containing the PTP-oc basal promoter and a por-
tion of the 5 0-UTR sequence of murine PTP-oc gene (Fig. 1).
Transfection of RAW264.7 cells with the pNTK-pPTP-oc
replacement targeting plasmid by electroporation resulted in
homologous recombination in 10% of the transfected cells,
as 10% of the transfected RAW264.7 cells survived in theFig. 2. Deletion of PTP-oc promoter by homologous recombination complete
RAW264.7 cells. Heterozygous PTP-oc KO RAW264.7 cells were produced a
parental RAW264.7 cells (RAW) and the PTP-oc KO cells (KO) was asse
corresponding GAPDH PCR transcript in two separate pools of RAW cells
corresponding GAPDH PCR transcript in a pool of RAW and KO cells. R
included for comparison.G418/GANC-containing selection medium. The homologous
recombinant cells were selected and expanded in the selection
medium for three weeks, at which time a large number of col-
onies of homologous recombinant cells were evident.
To conﬁrm that the homologous recombination approach
successfully knocked out PTP-oc expression without aﬀecting
Glepp1 expression, the expression of PTP-oc and Glepp1 genely abolished PTP-oc expression, but did not aﬀect Glepp1 expression in
s described in Section 2. Expression of PTP-oc and Glepp1 gene in the
ssed by RT-PCR. Top panels show the PTP-oc PCR transcript and
and the KO cells. Bottom panels show the Glepp1 PCR transcript and
T-PCR products of the total RNA from a mouse brain tissue were
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by RT-PCR and compared with that in the parental cells.
Fig. 2 showed that while parental RAW264.7 cells expressed
signiﬁcant amounts of PTP-oc mRNA, the PTP-oc expression
was completely abolished in the homologous recombinant
cells. In contrast, the Glepp1 gene expression in the homolo-
gous recombinant cells was not diﬀerent from that in parental
RAW264.7 cells. These data provide compelling evidence that
PTP-oc gene expression could be knocked out without aﬀect-
ing Glepp1 gene expression through targeted deletion of the
(pPTP-oc). On the other hand, our homologous recombination
strategy deleted, not only the PTP-oc basal promoter, but also
the transcription start site and a part of the 5 0-UTR sequence
of murine PTP-oc. Thus, it is possible that the abrogation of
PTP-oc expression was due also to the removal of the PTP-
oc transcription start site. Nevertheless, the fact that our strat-
egy resulted in complete abrogation of PTP-oc expression but
maintaining the Glepp1 expression conﬁrms the feasibility of
this novel approach.
Homologous recombination procedures frequently yielded
heterozygous recombinant cells in that only the gene-of-inter-
est on the dominant allele was inactivated or deleted [16]. The
pNTK used in this study contained a point-mutated neo gene
that reduced the activity of PGK promoter, allowing the use of
higher concentrations of G418 to kill oﬀ heterozygous cells
with only one copy of the neo gene. This would permit selec-
tion of homozygous homologous recombinant with an in-
creased G418 concentration [17]. Because all of the
recombinant cells were killed oﬀ when the amount of G418
in the selection medium was doubled to 0.8 mg/ml, the homol-
ogous recombinant cells obtained in this study were heterozy-
gous. The PTP-oc deﬁciency in these heterozygous PTP-oc KO
cells was relatively transient, as they started to express the
PTP-oc mRNA and protein in 1- to 2-months after the
three-week selection and expansion (Fig. 3). In fact, there
was no apparent diﬀerence in the PTP-oc expression level be-
tween these heterozygous PTP-oc KO cells and the parental
RAW264.7 cells after two months (data not shown). The tran-
sient nature of the heterozygous KO cells is well known [18]
and is most likely because the undeleted (pPTP-oc) gene onFig. 3. Heterozygous PTP-oc KO cells began to express PTP-oc gene
approximately 2 months after the homologous recombination proce-
dure. Heterozygous PTP-oc KO cells were generated, selected, and
expanded for 3 weeks as described in Section 2. Approximately 5 weeks
later, the PTP-oc gene expression level of these heterozygous PTP-oc
KO cells were analyzed by RT-PCR (top) and Western immunoblot,
and the PTP-oc expression level was compared to that of the parental
RAW264.7 cells.the recessive allele of the heterozygous recombinant cells grad-
ually became dominant and started driving the expression of
PTP-oc. The transient nature of PTP-oc-deﬁciency in the het-
erozygous recombinant cells due to subsequent activation of
the recessive (pPTP-oc) could limit the usefulness of these het-
erozygous recombinant cells. On the other hand, because these
heterozygous PTP-oc KO cells were completely PTP-oc deﬁ-
cient for almost two months, they should still be useful in stud-
ies to assess eﬀects of PTP-oc deﬁciency on osteoclast
formation and function.
We should emphasize that although our strategy to suppress
PTP-oc expression by promoter deletion through homologous
recombination yielded only heterozygous PTP-oc KO cells,
our approach has three very important advantages over the
commonly used strategies to knock down gene expression,
such as siRNA or antisense approaches for studies of PTP-
oc gene function. First, our promoter deletion approach
yielded cells that were completely devoid of PTP-oc, while
the gene knock down strategies yielded cells with residual gene
expression, that sometimes could be as high as 30–40% of the
basal expression level. The residual PTP-oc activity could con-
found interpretations of the results. Second, contrary to our
homologous recombination-based promoter deletion ap-
proach, which speciﬁcally knocked out PTP-oc expression,
the siRNA or antisense strategies are much less speciﬁc in that
target-complementary siRNAs (or antisense oligos) can also
target other mRNAs containing sequence segments that are
partially complementary to the siRNA, leading to oﬀ-target
gene silencing eﬀects [19]. Third, because the PTP-oc mRNA
shares sequence identity with the 3 0 end of the Glepp1 mRNA,
the siRNA or antisense strategies would inhibit both PTP-oc
and Glepp1 expression and function.
The abolition of PTP-oc expression in the homologous re-
combinant RAW264.7 cells did not signiﬁcantly alter the cell
morphology (data not shown). The cell population growth rate
of the homologous recombinant RAW264.7 cells was 60%
slower than that of the parental cells, as it had taken almost
three times as long for the PTP-oc deﬁcient RAW264.7 cells
to reach equivalent conﬂuence as the parental cells. The appar-
ent slower growth rate was not due entirely to the presence ofFig. 4. Deﬁciency in PTP-oc expression abolished the ability of
RAW264.7 cells to undergo RANKL-mediated diﬀerentiation into
TRACP-positive, multinucleated osteoclast-like cells. Parental
RAW264.7 cells (top panels) or PTP-oc-deﬁcient RAW264.7 cells
(bottom panel) were treated with (right panels) or without (left panels)
100 ng/ml sRANKL in 10% FBS for 7 days. Multinucleated giant
osteoclast-like cells were stained positively (red) for TRACP.
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grew signiﬁcantly slower than the parental cells in the absence
of the antibiotics. Because expression of the PD-PTP-oc mu-
tant or suppression of PTP-oc expression with a speciﬁc siR-
NA in RAW264.7 cells increased their apoptosis and cell
death [5], it is possible that the slower population growth rate
in the PTP-oc-deﬁcient cells were due both to a reduced prolif-
eration and an enhanced cell death. The possibility that PTP-
oc could also regulate the proliferation of the pre-osteoclastic
RAW264.7 cells will be addressed in our future studies.
Contrary to the parental RAW264.7 cells, which were diﬀer-
entiated into osteoclast-like cells in response to the sRANKL
treatment, the PTP-oc-deﬁcient RAW264.7 cells failed to form
any discernible numbers of TRACP-positive, multinucleated,
osteoclast-like cells (Fig. 4). These ﬁndings are in congruent
with our previous observations that expression of the PD-
PTP-oc mutant or suppression of PTP-oc expression with a
siRNA reduced the sRANKL-mediated formation of osteo-
clast-like cells from the pre-osteoclastic human U937 or mur-
ine RAW264.7 cells [3,5]. These ﬁndings conﬁrm our
contention that PTP-oc expression is required for the
RANKL-mediated osteoclastic diﬀerentiation of RAW264.7
cells.
The molecular mechanism by which PTP-oc regulates the
RANKL-mediated osteoclastic diﬀerentiation is not known.
Although our in vitro studies have suggested that PTP-oc en-
hances the bone resorption activity of osteoclasts in part
through the activation of the c-Src protein-tyrosine kinase
activity [2–5], it is highly unlikely that PTP-oc regulates osteo-
clastic diﬀerentiation also through the c-Src signaling pathway
[6]. Previous studies in knockout mice have revealed that sev-
eral transcription factors, such as c-fos [20], microphthalmia-
assoicated transcription factor (Mitf) [21], and the hematopoi-
etic transcription factor, PU.1 [22], each plays a critical role in
osteoclast diﬀerentiation and formation as mice deﬁcient in
these transcription factors displaced an osteopetrotic pheno-
type, characterized by the complete lack of osteoclasts. Thus,
we tested whether the expression of c-fos, Mitf, and PU.1
could be aﬀected by the PTP-oc deﬁciency by real-time RT-
PCR. We reasoned that if these transcription factors were
mediators of PTP-oc, knocking out PTP-oc expression shouldFig. 5. Deﬁciency in PTP-oc expression did not aﬀect the expression
level of c-Fos, Mitf, PU.1, or RANK in RAW264.7 cells. The mRNA
levels for c-Fos, Mitf, PU.1, and RANKL (normalized against the
housekeeping gene, b-actin) were measured by real-time RT-PCR.
Results are shown in change in cycle threshold (DCT) between the test
gene and b-actin (means ± S.E.M., n = 3). N.S. = not signiﬁcant.also alter the expression levels of these transcription factor.
Since the cellular actions of sRANKL are initiated through
its cognate receptor, RANK, the expression level of RANK
was also included in the study. Fig. 5 shows that PTP-oc deﬁ-
ciency did not appear to aﬀect the expression levels of c-fos,
Mitf, PU.1, or RANK. These data do not support a regulatory
role of these transcription factors in the PTP-oc-induced
RANKL-mediated osteoclastic diﬀerentiation of RAW264.7
cells. However, they also did not preclude the possibility that
the PTP-oc signaling pathway may act as a downstream signal-
ing pathway to these transcription factors. The knowledge of
the identity and/or functions of the cellular substrates of
PTP-oc in osteoclast precursor cells would be required for a
better understanding of the molecular mechanism whereby
PTP-oc acts to promote osteoclastic diﬀerentiation.
In summary, this study has demonstrated for the ﬁrst time
that it is feasible to knock out PTP-oc gene expression but
maintain the Glepp1 expression through targeted deletion of
the PTP-oc basal promoter by homologous recombination.
As such, this study provides important ground work informa-
tion for the design of our future work on the generation of
PTP-oc KO mice. Studies with PTP-oc deﬁcient RAW264.7
cells also conﬁrmed an important regulatory role for PTP-oc
in the RANKL-mediated osteoclastic diﬀerentiation of
RAW264.7 cells.
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